Medifast (MED)
Medifast Revenue Growth: 19.69%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
MED Revenue Growth Rankings
| Overall | 75th percentile | 1068 of 4358 |
| Sector | 77th percentile | 193 of 845 in Services |
| Industry | 75th percentile | 8 of 33 in Specialty Retail, Other |
MED Revenue Growth Range, Past 5 Years
| Minimum | 10.39% | Dec 2011 |
| Maximum | 75.08% | Mar 2010 |
| Average | 34.52% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these MED related companies
MED News
$MED purchased 150,000 shares of its common this week at cost basis of $18.34 http://stks.co/3zoW
about 14 hours ago by WallStreetBean
about 14 hours ago by WallStreetBean
$VVUS still long 2/3 sadly wt loss & diabetes drugs a growth industry. watch techncls for timing tho. $HLF $WTW $MED are done imho,
about 13 days ago by TrendHunter
about 13 days ago by TrendHunter
$HLF $WTW should get more down pressure with $ARNA approval imho. These remain as shorts. $MED is an oddity, perhaps just a short sqz
about 16 days ago by TrendHunter
about 16 days ago by TrendHunter
Auriga Reiterates a 'Buy' on Medifast (MED); Still Like Long-Term, But Cutting Estimates on Mixed Results
May 09, 10:47AM Street Insider
May 09, 10:47AM Street Insider
Mercadolibre, Gulfport Energy Corporation Among Stocks Gapping Down Wednesday
May 09, 10:31AM Fox Business
May 09, 10:31AM Fox Business
$MED is 6.1% up since open on unusual high volume but still -7.6% down since close.
about 17 days ago by TradeBot
about 17 days ago by TradeBot
$MED 200 Day SMA Cross - Price crossed below 200 day SMA (16.4047). Confirmed by volume.
about 17 days ago by TradeIdeasQuant
about 17 days ago by TradeIdeasQuant
Listen to $MED Q1 2012 earnings call - live at 04:30 PM, ondemand after - http://stks.co/3jHT
about 18 days ago by earningscast
about 18 days ago by earningscast
$MED i will risk it. With new MGM i believe that might want to prove something as well. Odds seem good.
about 18 days ago by nobr3ga
about 18 days ago by nobr3ga
@nobr3ga $MED fundies look really good to me going into EPS, but....will they look good coming out? That's the ?
about 18 days ago by WallStreetBean
about 18 days ago by WallStreetBean
@WallStreetBean $MED has a good 50% retracement. $HLF had a great Q, but were pyramid scheme operations. With regards to $WTW I dnt know
about 18 days ago by nobr3ga
about 18 days ago by nobr3ga
@nobr3ga been long $MED for a while but feeling a bit squeamish in light of recent Q's from $HLF and $WTW. Maybe they will break trend.
about 18 days ago by WallStreetBean
about 18 days ago by WallStreetBean
Competitor $MED reports 5/8. Keep Einhorn away! RT @harmongreg It may be time to give Herb a new Life, if you know what I mean $$
about 21 days ago by WallStreetBean
about 21 days ago by WallStreetBean
$HLF $WTW $MED seems like trading community thinks drugs $VVUS etc are the wt loss future. The American way, dont have self cntrl use drugs.
about 24 days ago by TrendHunter
about 24 days ago by TrendHunter
Surprised $MED held up as well as it did today after $HLF's punishment.
about 25 days ago by WallStreetBean
about 25 days ago by WallStreetBean
Medifast, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2012
Apr 24, 4:05PM PR Newswire
Apr 24, 4:05PM PR Newswire
$MED more than 20% float is short with about 12 days to cover. Bloodsport.
about 39 days ago by WallStreetBean
about 39 days ago by WallStreetBean
Medifast continues to make investors fat. $MED number 10 overall today. Great Chart.
about 39 days ago by billgunderson
about 39 days ago by billgunderson
Canaccord Genuity Maintains a 'Buy' on Medifast (MED); Limited Downside, But Waiting For Clarity To Upside
Apr 10, 9:51AM Street Insider
Apr 10, 9:51AM Street Insider
don't know why but not complaining. RT @bricktop13 $MED breaking out of an 8-month base.
about 54 days ago by WallStreetBean
about 54 days ago by WallStreetBean
Auriga Reiterates a 'Buy' on Medifast (MED), but Cutting Numbers on Growing Pains
Mar 14, 1:47PM Street Insider
Mar 14, 1:47PM Street Insider
Wedbush Maintains an 'Outperform' on Medifast (MED); Mixed Q4; Raising Estimates on Accelerating Outlook
Mar 14, 1:17PM Street Insider
Mar 14, 1:17PM Street Insider
Medifast, Inc. Announces Fourth Quarter and Fiscal Year 2011 Financial Results
Mar 13, 4:05PM PR Newswire
Mar 13, 4:05PM PR Newswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| MED | 18.60 | +0.08 | +0.43% | 288.49M |
| MEAD | 3.54 | -0.04 | -1.03% | 4.354M |
| MDR | 10.38 | +0.09 | +0.87% | 2.440B |
| MDM | 4.11 | +0.16 | +4.05% | 330.24M |
| MDD | 24.88 | +0.01 | +0.04% | |
| MDCA | 9.55 | +0.05 | +0.53% | 295.29M |
| MCY | 43.67 | -0.29 | -0.66% | 2.397B |
| MCS | 13.68 | -0.20 | -1.44% | 400.14M |
| MCRS | 54.13 | +0.01 | +0.02% | 4.327B |
| MCO | 37.36 | +0.11 | +0.30% | 8.343B |